Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody drug conjugate (ADC)-based therapies, announced a multi-year collaboration with ...

Oxford BioTherapeutics (OBT ... antibodies arising from the collaboration make it to market. According to its pipeline listing, the Roche alliance covers some 12 separate programmes.

Oxford BioTherapeutics (OBT), a clinical-stage oncology firm, has announced a long-term partnership with Roche to develop new antibody-based cancer therapies. This collaboration marks a ...

Net Loss: For the first quarter of 2025, the Company generated a net loss attributable to its shareholders of $19.6 million, ...

Oxford Biotherapeutics Ltd. is partnering with Roche AG to expand the current field of tumor antigens that can be drugged with antibodies, as part of a potential $1 billion-plus agreement. The ...

In January 2025, Boehringer signed two further licensing agreements to deepen its pipeline ... of a long-standing partnership with Oxford BioTherapeutics, under which Boehringer exercised an ...